BEAM
Price
$24.84
Change
-$0.09 (-0.36%)
Updated
Oct 21 closing price
Capitalization
2.57B
12 days until earnings call
Intraday BUY SELL Signals
CRSP
Price
$50.50
Change
+$0.62 (+1.24%)
Updated
Oct 21 closing price
Capitalization
4.88B
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs CRSP

BEAM vs CRSP Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. CRSP commentary
Oct 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and CRSP is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BEAM with price predictions
Oct 21, 2026

BEAM sees its Stochastic Oscillator ascending out of oversold territory

On October 20, 2026, the Stochastic Oscillator for BEAM moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 50 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BEAM's RSI Oscillator exited the oversold zone, 20 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on BEAM as a result. In 69 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for BEAM just turned positive on September 29, 2026. Looking at past instances where BEAM's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.

Following a +6.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 196 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for BEAM entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.404) is normal, around the industry mean (2.988). P/E Ratio (-36.000) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. BEAM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for CRSP with price predictions
Oct 21, 2026

CRSP in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 08, 2026

CRSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 36 cases where CRSP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 65 cases where CRSP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The 50-day moving average for CRSP moved above the 200-day moving average on September 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in 209 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 78 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for CRSP turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

CRSP moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 70%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for CRSP entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.796) is normal, around the industry mean (2.988). P/E Ratio (-10.722) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. CRSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BEAM vs CRSP: Fundamental Ratings
BEAM
CRSP
OUTLOOK RATING
1..100
768
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9296
PRICE GROWTH RATING
1..100
7062
P/E GROWTH RATING
1..100
3350
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (6) in the null industry is in the same range as CRSP (24) in the Biotechnology industry. This means that BEAM’s stock grew similarly to CRSP’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as CRSP (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to CRSP’s over the last 12 months.

BEAM's SMR Rating (92) in the null industry is in the same range as CRSP (96) in the Biotechnology industry. This means that BEAM’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's Price Growth Rating (62) in the Biotechnology industry is in the same range as BEAM (70) in the null industry. This means that CRSP’s stock grew similarly to BEAM’s over the last 12 months.

BEAM's P/E Growth Rating (33) in the null industry is in the same range as CRSP (50) in the Biotechnology industry. This means that BEAM’s stock grew similarly to CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMCRSP
RSI
ODDS (%)
Bullish Trend 4 days ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 8 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 10 days ago
81%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
76%
COMPARISON
Comparison
Oct 22, 2026
Stock price -- (BEAM: $24.84 vs. CRSP: $50.50)
Brand notoriety: BEAM and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 60% vs. CRSP: 78%
Market capitalization -- BEAM: $2.57B vs. CRSP: $4.88B
BEAM [@Biotechnology] is valued at $2.57B. CRSP’s [@Biotechnology] market capitalization is $4.88B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.95B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 2 FA rating(s) are green while CRSP’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 2 green, 3 red.
  • CRSP’s FA Score: 1 green, 4 red.
According to our system of comparison, CRSP is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while CRSP’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 2 bearish.
  • CRSP’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than CRSP.

Price Growth

BEAM (@Biotechnology) experienced а +5.03% price change this week, while CRSP (@Biotechnology) price change was +0.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.90%. For the same industry, the average monthly price growth was -15.91%, and the average quarterly price growth was -14.30%.

Reported Earning Dates

BEAM is expected to report earnings on Nov 03, 2026.

CRSP is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (+1.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BEAM
Daily Signal:
Gain/Loss:
CRSP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FV75.110.57
+0.77%
First Trust Dorsey Wright Focus 5 ETF (FV)
KMAY29.570.05
+0.16%
Innovator U.S. Small Cap Power Buffer ETF - May (KMAY)
IBHG21.750.01
+0.05%
iShares iBonds 2027 Term High Yield and Income ETF (IBHG)
PFD10.51N/A
N/A
Flaherty & Crumrine Preferred and Income Fund
SETH32.35-0.80
-2.40%
ProShares Short Ether ETF (SETH)